GLP-1 Research Compound Regulatory Tracker (2025-2026)

This is a factual, regulatory-focused roundup of where the three highest-profile GLP-1-class compounds — semaglutide, tirzepatide, and retatrutide — stand as of mid-2026. It does not cover dosing or personal use; it tracks FDA approval status, compounding restrictions, and clinical-trial progress as reported by the FDA, sponsor press releases, and state pharmacy regulators.

Semaglutide: approved, but compounding is closing down

Semaglutide is FDA-approved under three brand names for distinct indications: Ozempic (type 2 diabetes; cardiovascular and kidney risk reduction, added 2025), Rybelsus (oral, type 2 diabetes, approved 2019), and Wegovy (chronic weight management, approved 2021; cardiovascular risk reduction in adults with established cardiovascular disease, added 2024; an oral Wegovy tablet approved in 2025 based on the OASIS 4 trial). Compounded, non-brand semaglutide is a separate regulatory category and is not FDA-approved.

As of mid-2025, the FDA proposed permanently excluding semaglutide from the list of bulk substances 503A and 503B compounders may use. By July 2025, the agency had logged over 1,150 adverse event reports tied to compounded semaglutide and tirzepatide combined, many linked to dosing errors, product-quality issues, and in some cases fraudulent labeling.

Tirzepatide: the same compounding restriction, on a shorter timeline

Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes, approved May 2022) and Zepbound (chronic weight management, approved November 2023; obstructive sleep apnea in adults with obesity, added December 2024). As with semaglutide, compounded tirzepatide is a separate, non-approved category and has been the subject of direct FDA enforcement.

The FDA logged more than 320 adverse event reports specifically tied to compounded tirzepatide as of July 2025 (part of the 1,150-plus combined figure with semaglutide), largely linked to dosing errors, and in 2025 proposed excluding tirzepatide from the substances 503A/503B compounding pharmacies may legally use.

The federal litigation over 'shortage resolved' determinations

The compounding restrictions followed FDA determinations that the tirzepatide (December 2024) and semaglutide (February 2025) shortages were resolved, which closed the door on 503B mass compounding of 'copies' of the branded drugs while narrow, patient-specific 503A compounding with documented medical necessity remains legal. The Outsourcing Facilities Association challenged both determinations in the Northern District of Texas; the court denied preliminary injunctions against the tirzepatide decision on March 5, 2025 (Case 4:24-cv-00953) and against the semaglutide decision on April 24, 2025 (Case 4:25-cv-00174), reinforcing the closure of mass compounding nationally.

In March 2026, the FDA issued roughly 30 warning letters in a single day to telehealth companies over misleading compounded-GLP-1 marketing claims — part of a broader national enforcement wave, not an isolated action.

State-level compounding rules are diverging

State pharmacy boards have layered additional restrictions on top of the federal baseline, and the specifics vary meaningfully by state. California's Board of Pharmacy comprehensively rewrote its compounding regulations effective October 1, 2025, tightening the 'essentially a copy' analysis and explicitly prohibiting salt forms such as semaglutide sodium or acetate in compounding — a standard legal analysts describe as the strictest codified compounding rule nationally. Texas regulators reportedly require documented clinical justification beyond federal minimums and restrict acceptable formulations to base-form (not salt-form) semaglutide or tirzepatide with a Certificate of Analysis.

Multiple state attorneys general, including California's, Texas's, New York's, and Massachusetts's, launched investigations into direct-to-consumer telehealth weight-loss platforms in 2025-2026, on theories including unauthorized practice of medicine and deceptive trade practices.

Retatrutide: still investigational, Phase 3 ongoing

Retatrutide, developed by Eli Lilly as a triple agonist across the GIP, GLP-1, and glucagon receptors, remains in active Phase 3 development and has not received FDA approval for any indication. It is not legally available as a prescription drug. The TRIUMPH program (obesity/overweight, knee osteoarthritis, severe obesity with cardiovascular disease) and the TRANSCEND-T2D program (type 2 diabetes) have enrolled more than 5,800 participants combined and reported topline and detailed Phase 3 results through 2025-2026.

Because retatrutide has no approved formulation, any product sold under that name outside Lilly's clinical trial program is, by definition, an unapproved research chemical with no regulatory oversight of purity or manufacturing — a distinct legal and safety category from the FDA-approved GLP-1 drugs above.

Why this matters for vendor evaluation

This regulatory tightening is the backdrop for the vendor closures we've tracked separately: SwissChems, for instance, carries an unresolved December 2024 FDA warning letter (MARCS-CMS 695663) specifically over its semaglutide and retatrutide product pages marketing unapproved new drugs for human use. The compounds themselves aren't going away from clinical research, but the legal space around selling them as research chemicals is narrowing, and vendor-level compliance postures are worth checking against the regulatory facts above rather than a vendor's own characterization of its legal standing.